Boehringer completes Phase III studies of nintedanib
The two identical 52-week, double-blind, randomised, placebo-controlled trials with matching twice-daily 150mg dosing, inclusion criteria and endpoints enrolled a total of 970 patients in 20 countries. The annual
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.